Abstract: The invention relates to an active ingredient consisting of several polylysine compounds, said polylysine compounds consisting of at least one small molecule conjugated to a polylysine, said active ingredient comprising at least the following polylysine compounds: Coenzyme Q10-Polylysine Retinoic Acid-Polylysine Cysteine-Polylysine Taurine-Polylysine Glutathione-Polylysine, for use in humans or animals, to prevent strokes and/or treat the inflammatory phase following a stroke.

Abstract: The invention relates to an ex vivo method for detecting or monitoring the progression of a chronic degenerative disease, in a sample of human or animal biological fluid, by immunoassay for the presence of antibodies in the sample, including at least: one or more antibodies directed against at least one endobacterium, and one or more antibodies directed against a tryptophan oxidation product. The invention also relates to a kit for implementing such a method.

Abstract: The invention relates to an ex vivo method for detecting or monitoring the progression of a chronic proliferative disease, in a sample of human or animal serum or plasma, by immunoassay for the presence of antibodies in the sample, including at least one or several antibodies directed against benzo(a)pyrene. The invention also relates to a kit for implementing such a method.

Abstract: The invention relates to an ex vivo method for detecting or monitoring the progression of a chronic autoimmune disease, in a sample of human or animal biological fluid, by immunoassay for the presence of antibodies in the sample, including at least: one or more antibodies directed against at least one enterobacterium, and one or more antibodies directed against a product at the origin of or resulting from lipoperoxidation and/or one or more antibodies directed against a nitrated or nitrosylated product. The invention also relates to a kit for implementing such a method.

Abstract: The invention relates to an active ingredient consisting of several polylysine compounds, said polylysine compounds consisting of at least one small molecule conjugated to a polylysine, said active ingredient comprising at least the following polylysine compounds: Coenzyme Q10-Polylysine Retinoic Acid-Polylysine Cysteine-Polylysine Taurine-Polylysine Glutathione-Polylysine, for use in humans or animals, to prevent strokes and/or treat the inflammatory phase following a stroke.

Abstract: A polycomplex comprising multiple Poly-lysine compounds, said Poly-lysine compounds being composed of at least one small molecule conjugated with a Poly-lysine. Compositions comprising the polycomplex and methods for treating an amyotrophic lateral sclerosis patient, the methods comprising administering to the patient one or more of the compositions.

Abstract: The invention relates to a molecular complex comprising at least one polylysine conjugate (PLL), comprising a main PLL straight chain and at least one molecule F having an average molecular weight of between 50 daltons and 1000 daltons that is covalently bonded to said main chain, and at least one molecule M that is unstable in solution, the conjugate(s) and the molecule(s) M being bonded by means of a non-covalent bond. The invention also relates to a composition comprising a complex of this kind, to a method for obtaining said composition and use thereof, and to the use of one or more PLL-based conjugates for improving the hydrophilicity, the effectiveness, and the activity of a molecule that is unstable in solution, over a time period that is compatible with the use of said molecule.

Abstract: A polycomplex comprising multiple Poly-lysine compounds, said Poly-lysine compounds being composed of at least one small molecule conjugated with a Poly-lysine. Compositions comprising the polycomplex and methods for treating an amyotrophic lateral sclerosis patient, the methods comprising administering to the patient one or more of the compositions.

Abstract: Disclosed is a method for identifying and characterizing compounds conjugating at least one polylysine and at least one other molecule chosen from the acids, fatty acids, vitamins, amino acids, amino acid derivatives having a neurotransmitter activity and the active substances having a therapeutic effect, the method including at least: a step of identification, by infrared spectroscopy, and at least one characterization step chosen from: ultraviolet-visible absorption spectroscopy, gas phase chromatography, high-performance liquid phase chromatography.

Abstract: The invention relates to a molecular complex comprising at least one polylysine conjugate (PLL), comprising a main PLL straight chain and at least one molecule F having an average molecular weight of between 50 daltons and 1000 daltons that is covalently bonded to said main chain, and at least one molecule M that is unstable in solution, the conjugate(s) and the molecule(s) M being bonded by means of a non-covalent bond. The invention also relates to a composition comprising a complex of this kind, to a method for obtaining said composition and use thereof, and to the use of one or more PLL-based conjugates for improving the hydrophilicity, the effectiveness, and the activity of a molecule that is unstable in solution, over a time period that is compatible with the use of said molecule.

Abstract: Disclosed is a method for identifying and characterizing compounds conjugating at least one polylysine and at least one other molecule chosen from the acids, fatty acids, vitamins, amino acids, amino acid derivatives having a neurotransmitter activity and the active substances having a therapeutic effect, the method including at least: a step of identification, by infrared spectroscopy, and at least one characterization step chosen from: ultraviolet-visible absorption spectroscopy, gas phase chromatography, high-performance liquid phase chromatography.

Abstract: A composition for controlling the progression of multiple sclerosis includes at least: One conjugate between poly-lysine and at least one fatty acid, and One conjugate between poly-lysine and at least one antioxidant, and One conjugate between poly-lysine and at least one amino acid derivative.

Abstract: The invention relates to the use of a composition for controlling the evolution of amyotrophic lateral sclerosis, characterised in that it comprises at least: a conjugate of poly-lysine and at least one anti-oxidant, and a conjugate of poly-lysine and at least one fatty acid. The invention also relates to a particular composition for controlling the evolution of amyotrophic lateral sclerosis.

Abstract: The invention relates to a method for detecting and supervising neurodegenerative diseases, which consists in detecting the presence of antibodies of the A-isotype and/or M-isotype which are directed against the antigens which are associated with these diseases. The invention also relates to a kit for the implementation of this method.

Abstract: A process for the production of an active molecule vector that can be applied in the biomedical field, includes the following stages: Diluting a monomer that has at least two NH2 groups that are separated by at least four carbons in water, Adjusting the pH to a value of between 6.5 and 7.5, Adding glutaraldehyde, OHC—(CH2)3—COH, and Awaiting the polycondensation reaction and the formation of imines, and Recovering the poly(monomer-G) that is obtained. The monomer is selected from among the L-ornithine, the L-lysine or the L-citrulline. Further described are the biomedical vector that is obtained, and the use as a vector of active molecules, such as fatty acids, antioxidants, vitamin-enriched compounds or neurotransmitters for having bacteriostatic, anti-allergenic, anti-parasitic, anti-predatory or antifungal, anti-inflammatory or immunomodulating activities.

Abstract: The object of the invention is a process for the production of a molecule vector that can be used in water treatment, able to trap heavy ions, characterized in that it comprises the following stages: Diluting ornithine, NH2—(CH2)3—CH(NH2)—COOH, in water, Adjusting the pH to a value of between 6.5 and 7.5, Adding glutaraldehyde, OHC—(CH2)3—COH, and Awaiting the polycondensation reaction and the formation of imines, and Recovering the poly(ornithine-G) that is obtained. The invention also covers the vector that is obtained and the use as heavy-ion sensors.

Abstract: The invention relates to a method for detecting and supervising neurodegenerative diseases, which consists in detecting the presence of antibodies of the A-isotype and/or M-isotype which are directed against the antigens which are associated with these diseases.

Abstract: A method of treating neurodegenerative diseases, infectious, traumatic or toxic neuropathies, degenerative diseases of the autoimmune type, neurodegenerative disorders resulting from genetic diseases or proliferative diseases with polylysine conjugates is disclosed. Polylysine conjugates are also disclosed.

Abstract: New antibodies capable of specifically identifying hapten groups, characterized by the fact that said hapten groups correspond to the formula:--NH--(CH.sub.2).sub.n --NH--Hapt.in whichn is a whole number between 4 and 6, and Hapt. is the residue of the hapten molecule of formula Hapt. --NH.sub.2 (--NH.sub.2 being a primary amine group) or of formula Hapt..dbd.NH (.dbd.NH being the imine of a guanidine type group);their preparation through immunization using immunogens of the formula:[M --NH--(CH.sub.2).sub.n NH--Hapt.].sub.xand their application, particularly in visualizing and determining the quantity of haptens.